 | Up a level |
Boegemann, Martin, Mikah, Phillip, Eminaga, Okyaz, Herrmann, Edwin, Papavassilis, Philipp Marius, Hinkelammert, Reemt, Semjonow, Axel, Schrader, Andres Jan and Krabbe, Laura-Maria (2015). Dynamic changes of alkaline phosphatase as surrogate for best clinical benefit and overall survival during very early abiraterone therapy compared to PSA-changes in bone metastatic castration resistant prostate cancer. J. Clin. Oncol., 33 (7). ALEXANDRIA: AMER SOC CLINICAL ONCOLOGY. ISSN 1527-7755
Boegemann, Martin, Mikah, Phillip, Eminaga, Okyaz, Herrmann, Edwin, Papavassilis, Philipp Marius, Hinkelammert, Reemt, Semjonow, Axel, Schrader, Andres Jan and Krabbe, Laura-Maria (2015). Dynamic changes of alkaline phosphatase as surrogate for best clinical benefit and overall survival during very early abiraterone therapy compared to PSA-changes in bone metastatic castration resistant prostate cancer. J. Clin. Oncol., 33 (7). ALEXANDRIA: AMER SOC CLINICAL ONCOLOGY. ISSN 1527-7755
Boegemann, Martin, Mikah, Phillip, Eminaga, Okyaz, Herrmann, Edwin, Papavassills, Philipp Marius, Semjonow, Axel and Krabbe, Laura-Maria (2014). Indicators of clinical response to abiraterone acetate (AA) men with metastatic castration-resistant-prostate-cancer (mCRPC). J. Clin. Oncol., 32 (15). ALEXANDRIA: AMER SOC CLINICAL ONCOLOGY. ISSN 1527-7755
Mikah, Phillip, Krabbe, Laura-Maria, Eminaga, Okyaz, Herrmann, Edwin, Papavassilis, Philipp, Hinkelammert, Reemt, Semjonow, Axel, Schrader, Andres-Jan and Boegemann, Martin (2016). Dynamic changes of alkaline phosphatase are strongly associated with PSA-decline and predict best clinical benefit earlier than PSA-changes under therapy with abiraterone acetate in bone metastatic castration resistant prostate cancer. BMC Cancer, 16. LONDON: BMC. ISSN 1471-2407